| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.9 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |